BERMUDA-Multiple semaglutide products recalled due to quality and packaging issues

- Advertisement -

HAMILTON, Bermuda, Sept 8, CMC – Bermudian health authorities have issued recalls for Semaglutide injection products noting that the recalls relate to product impurities, incorrect dose display, and packaging errors that may result in patients receiving the wrong dose.

The Ministry of Health said Semaglutide is a prescription medication used in adults to improve blood glucose control and, in some cases, support weight management. Accurate dosing is essential to ensure safe and effective treatment.

It said all pharmacies and medical warehouses in Bermuda have been formally notified.

“Ensuring the accuracy and safety of medications used by our community is essential. While these recalls stem from manufacturer quality and packaging issues, we are acting quickly to make sure patients and healthcare providers have clear information,” said Health Minister, Kim Wilson.

“Anyone who believes they may have received an affected product should contact their pharmacist immediately. Our healthcare teams are prepared to support patients and ensure continuity of safe treatment,” she added.

The ministry said the products manufactured in  Canada may result in wrong dose delivery due to mismatched pen and packaging with another product displaying a 2 mg dose in the dose window and deliver a 2 mg dose instead of the expected 0.25 mg or 0.5 mg dose.

The ministry is urging  persons taking the medication not use any affected product until they u have verified the lot number and confirmed whether their  supply is part of the recall.

In addition, they are being urged to return affected products to the pharmacy where they were purchased for replacement, alternative supply, and proper disposal as well as consult  their healthcare provider before discontinuing treatment or if they have concerns about dosing accuracy or adverse effects.

“If you are unsure whether your medication is affected, contact your pharmacy directly. Patients who received Semaglutide dispensed into vials or alternative packaging should note that the pharmacy name will be printed on the label and should contact that pharmacy to confirm whether their supply is affected,” the ministry added.

- Advertisement -